Introduction
The development of autologous antibody responses during early HIV-1 infection has become the subject of increasing interest, based on the premise that such specificities may define exposed vulnerabilities on the transmitted envelope, and inform the development of neutralization breadth. The appearance of autologous neutralizing antibodies (AnAb) occurs within months of infection in most HIV-1-infected individuals [1-4] and though such responses are often potent and rapidly drive neutralization escape, they are extremely strain specific. The specificities and number of these early antibodies that drive escape have recently become clearer.
Development of anti-HIV-1 antibodies
The first B-cell response to transmitted HIV-1 comprises binding antibodies that first develop within 8 days of detectable viremia and initially exist as antigen-antibody complexes [5 ] . These antibodies are followed by circulating anti-gp41 antibodies 5 days later, with anti-gp120 antibodies, primarily targeting the V3 loop, delayed a further 14 days. AnAb responses to HIV-1 develop later in infection, at about 12-20 weeks after infection in most individuals, with antibodies invariably showing strain specificity [1-4,6] especially in subtype C virus in which relatively higher titres and increased strain-specificity have been described [2] . Such AnAb responses persist during most of the course of disease but may wane during the symptomatic phase of infection perhaps reflecting the inability of the dysfunctional humoral immune system to respond to de-novo viral variants [4,7 ,8] . The strain specificity of AnAbs [1-4] and the genetic pressure evidenced on later env sequences [4, 7 ] suggest that these antibodies target the variable regions rather than more conserved structures of the envelope glycoprotein.
HIV-1 infection, do not contribute to autologous neutralization [9,10 ,11 ]. This fact is despite the finding that such antibodies have a broadly cross-reactive envelopebinding capacity and an extremely high neutralizing activity against viruses with artificially exposed V3 regions (such as the HIV-2 chimeric envelope engrafted with HIV-1 V3 loop) [9,10 ,11 ]. Similar observations using simian human immunodeficiency virus (SHIV) chimeras suggest that anti-V3 antibodies also play no substantial role in autologous neutralization during SHIV infection of monkeys [12 ] . This finding supports evidence that shows that anti-V3 antibodies play a minimal role in neutralization [13, 14] due to occlusion of the V3 loop within the trimeric Env [9,10 ,15-17].
V1V2 is a frequent target of autologous neutralizing antibodies
The role of V1V2 in shielding neutralization determinants is well recognized [15, 16, [18] [19] [20] [21] [22] . However, V1V2 may also act as a neutralization target in laboratoryadapted isolates [23] and primary viruses [1,11 ,24-30] . Use of reciprocal V1V2 chimeras suggested that the V1V2 region was principally responsible for the strain-specific AnAbs detected in plasma from SHIV-infected monkeys [12 ] . Similarly in HIV-1 infection, there is mounting evidence that the V1V2 loop is an early target of AnAbs. Transfer of early V1V2 sequences into a heterologous viral backbone resulted in transfer of neutralization sensitivity to autologous plasma [21] . In contrast, transfer of later/chronic V1V2 regions did not result in autologous neutralization sensitivity, suggesting that V1V2 may be a target of early AnAbs, with changes in later V1V2 sequences mediating escape [21] . In subtype C infection, a similar approach using chimeric Env derived from transmission pairs suggested that V1V2 might contain AnAb epitopes in some cases, in addition to the more general role of V1V2 in shielding neutralization determinants [29]. This suggestion was confirmed using chimeras constructed between envelopes derived from early subtype C infection [11 ] and by the examination of neutralization escape variants which also implicated the V1V2 region as a target of AnAbs [11 ,31] (Moore et al., in preparation; Rong et al., in preparation). Confirmation of the role of V1V2 as an AnAb target comes from the isolation of anti-V1V2 antibodies that recognise glycandependent epitopes from B-cell hybridomas of a subtype C-infected individual (Rong et al., in preparation) . The V1V2 region, therefore, appears to be commonly immunogenic in early HIV-1 and SHIV infections. However, the nature of these epitopes requires further elucidation, as it still not known whether these neutralizing anti-V1V2 antibodies, like those increasingly isolated through screening by neutralization rather than binding [32] , recognize epitopes only apparent in the trimeric structure of the envelope.
The role of the V4 and V5 regions in autologous neutralization
The role of the V4 and V5 loops as AnAb targets is less clear. The V4 region has been proposed to contribute to the formation of quaternary epitopes in conjunction with the C3 region in subtype C viruses [11 ,33] (see below for details), but, independently, the V4 does not appear to be a significant AnAb target, although changes in this region may mediate neutralization escape [34] . Similarly, the use of chimeras suggested only a marginal role for V5 as a target of AnAbs in early HIV-1 infection [11 ]; however, again changes within the V5 may effectively mediate escape from AnAbs (Moore et al., in preparation; Rong et al., in preparation). The mechanism whereby such escape occurs remains to be defined, but it may be via modulation of proximal epitopes (Moore et al., in preparation; Rong et al., in preparation) with which V5 interacts, such as the adjacent CD4-binding site (CD4bs) [35] .
C3: a subtype-specific neutralization target?
In addition to the variable regions, the C3 region located in the outer domain of gp120, slightly upstream of the V3 loop, has been implicated as a neutralization target in subtype C viruses [33, 36] and is under strong diversifying pressure [37] . Furthermore, there are structural differences between subtypes B and C in the alpha 2 (a2)-helix of C3 [36] , which increased exposure in subtype C viruses. In addition, neutralization resistance mutations were frequently located within the a2-helix of Zambian subtype C viruses [33] and in Indian subtype C viruses [38] . It has, therefore, been proposed that AnAbs directly target the a2-helix in subtype C viruses [11 , 33, 36] . However, chimeras that transfer the a2-helix between resistant donor Env and sensitive recipient Env from subtype C transmission pairs did not alter the AnAb phenotype, which suggested that the a2-helix must be associated with other regions of Env for the formation of AnAb epitopes [33] , with occasional exceptions in which the a2-helix may serve as an AnAb target independently of V4 [11 ] (Moore et al., in preparation). The a2-helix may contribute to the quaternary structure of the trimer and so affect neutralization epitopes, possibly via the strong interactions that this region has with the V4 loop, or the b-10, b-11, b-14 and b-24 strands [33] . That finding was confirmed by the use of reciprocal chimeras in which transfer of the C3 region in conjunction with the V4 loop (C3V4) resulted in transfer of neutralization sensitivity, suggesting that the C3V4 region was a major target of AnAbs in subtype C HIV-1 infection [11 ] . The observation that within the a2-helix in subtype C, amino acid changes frequently resulted in charge changes, unlike subtype B in which variable positions tend to maintain similar charge, led to the suggestion that switching of charges may facilitate immune escape [36] . This suggestion was supported by the observation that, in subtype C, neutralization escape was associated with mutations within the a2-helix that resulted in charge changes (Moore et al., in preparation).
In addition to the a2-helix, the C3 region also contains the highly variable b-14 strand as well as the conserved b-15 strand and a3-helix, which contain elements of the CD4bs, so it is also possible the anti-C3V4 reactivity is mediated by anti-CD4bs antibodies that are strain-specific. Strain specific anti-CD4bs antibodies may not be entirely surprising as even the monoclonal CD4bs nAb IgG1b12, which is characterizedasbroadlycross-neutralizing,neutralizesonly approximately two-thirds of primary viruses [13] . Furthermore, there is evidence that the functional CD4 binding regionissmallerthanthestructural epitopeofIgG1b12 [39] , perhaps allowing some flexibility in secondary binding sites to other nonconserved residues [40] . This finding may be explained in part also by recent data that compared IgG1b12 with a nonneutralizing monoclonal antibody b13. Although these mAbs share overlapping binding sites, the angle at which these antibodies approach the trimer and the compatibility of such binding with the trimeric spike, including the quaternary location of the V1V2 loops [41] , may determine the neutralizing capacity and specificity of such CD4bs antibodies [42] .
gp41 as a target of autologous neutralizing antibodies
The majority of early AnAb responses to transmitted HIV-1 variants seems to be directed at the gp120 in line with the high levels of positive selection focused here [7 ] . Neutralizing antibodies that target the membrane proximal external region (MPER) of gp41 may develop within the first year of infection in some individuals [1]; however, their contribution to autologous neutralization has not been well defined. Recent data from one individual in whom adsorption of anti-MPER antibodies resulted in abrogation of cross-neutralization showed that the effect of adsorption on autologous neutralization was marginal, suggesting that these broadly cross-reactive anti-MPER did not substantially contribute to autologous neutralization in this case [43] . In contrast, the identification of 4E10-resistant variants in an HIV-1-infected individual exhibiting an anti-MPER antibody response suggested immune escape from AnAb responses targeting this region [44] . Analysis of neutralization escape in subtype C-infected individuals suggested a role for the ectodomain of gp41 in neutralization escape although it was not clear whether the AnAbs in this case targeted gp41 directly or whether escape occurred via modulation of distal epitopes (Rong et al., in preparation) . It is noteworthy that, in the above cases, anti-gp41 antibody pressure was observed after 1 year of infection and considerably delayed compared with the primary autologous neutralization response.
AnAb pressure and evolution of the envelope Much of the variation that occurs in the Env during early infection is thought to be the result of pressure exerted by AnAbs [3, 4, 45] . Later in infection, selection pressure on the envelope is decreased [7 ], perhaps reflecting the diminishing AnAb response [4, 7 ] . Neutralization escape has been documented in early HIV-1 subtype B viruses . However, in studies of chronically infected mothers transmitting HIV-1 to their children [55] and in long-term nonprogressors [8, 56 ] , both sensitive and relatively resistant variants were detected among the quasispecies. A similar pattern of persistence of neutralization sensitive variants was observed in a typical progressor who had notably broad and potent antibody responses (K.A. Bosch and J. Overbaugh, unpublished observation). The persistence of sensitive variants may result from continuous reversion of less fit escape variants or persistent release of pre-escape variants from cell reservoirs. This finding suggests that the envelope glycoprotein may have limited plasticity with which to mediate continuous escape from the autologous antibody response.
Sequential specificities arise during early HIV-1 infection
Examination of neutralization escape in HIV-1 infection suggests that there may be limited AnAb specificities driving escape during early infection [31] (Moore et al., in preparation). In four subtype C-infected individuals, between 1 and 2 antibody specificities appeared to mediate autologous neutralization during the first year of infection (Moore et al., in preparation). Interestingly, in cases in which more than one specificity was present, these arose sequentially during the first year [31] , sometimes requiring months of infection (Moore et al., in preparation). This observation suggests the possibility of an immunological hierarchy, with delayed development of selected responses, in line with the hierarchical binding antibody responses that develop in the very early stages of infection [5 ], prior to the development of AnAbs. It is also possible that changes that develop across the envelope during the first months of infection in response to neutralization escape, and other selection pressures, affect the conformation and exposure of the secondary AnAb target, facilitating presentation of this region to the immune system only at a later time point (Moore et al., in preparation). This phenomenon may ultimately result in the exposure of more conserved regions that will induce broadly crossneutralizing antibodies.
AnAbs and prevention of superinfection/ control of viremia
The effect of AnAbs on controlling viral load and preventing superinfection is unclear. It has been suggested that AnAbs are ineffective in individuals with high viral loads due to the continuous generation of escape variants, but that they may play a role in maintenance of low viral loads in controllers [56 ] or during early infection, in which viral diversity is relatively low (Moore et al., in preparation). In one individual, a decrease in the viral load was temporally associated with the development of an AnAb response, followed by a rebound as neutralization escape occurred. This finding suggested the possibility that AnAbs may, in the short term, have affected viral load, with this effect abrogated by the emergence of neutralization-resistant variants (Moore et al., in preparation). Interestingly, relatively high titres of AnAbs were needed before sufficient pressure was exerted on the overall population, forcing escape to occur (Moore et al., in preparation), perhaps reflecting the 'soft' selection pressure exerted by AnAbs [6].
The requirement for relatively high antibody titres is supported by the observation that superinfection may occur in the presence of low levels of preexisting crossneutralizing antibodies that have been raised against the initial infecting strain [57 ] . Furthermore, theoretical calculations of protective in-vivo titres from passive transfer studies suggested that nAb titres in excess of 1 : 200 were required for protection during acute infection and increasing to titres exceeding 1 : 1000 during chronic infection [58 ] . These studies are in line with data from animals [59] [60] [61] . The inhibitory potential of even the best known monoclonal nAbs, namely IgG1b12, 2F5, 4E10 and 2G12, is relatively low compared with most antiretroviral drugs [62 ,63] , suggesting that high antibody titres may be needed to achieve protective levels.
Conclusion
The now routine use of the recombinant pseudovirus assay [14, 64, 65] , coupled with the use of standardized methodologies to amplify envelopes from single-genome templates [66, 67] , has facilitated detailed characterization of early AnAb responses and resultant escape variants (Moore et al., in preparation; Rong et al., in preparation) [67] . In addition, use of chimeric viruses has greatly advanced our understanding of the specificities of AnAbs [1,9,10 ,11 ,12 ,21,29,68] . Future research aimed at understanding the targets of AnAbs should make use of methods that have been recently employed to dissect the specificities of broadly cross-reactive antibodies [69] [70] [71] [72] [73] . Specifically, the use of methodologies such as adsorptions using soluble gp120 will clarify whether AnAbs recognize epitopes recapitulated on monomeric proteins or whether trimeric structures are required. Perhaps the most direct and powerful method for characterizing specificities mediating autologous neutralization is the isolation of monoclonal AnAbs (Rong et al., in preparation) [74] . Use of novel methods for highthroughput molecular generation of AnAbs will facilitate the rapid generation of monoclonal AnAbs [75] [76] [77] [78] , which will make fine mapping of epitopes feasible.
Further characterization of the nature of AnAb responses continues to be important for two reasons. First, much attention in the last year has been directed at defining the specificities of broadly cross-reactive nAbs (reviewed by Binley in this issue); however, the mechanisms that lead to the development of cross-neutralizing capacity are not clear. The development of breadth is likely to be dependent in part on the autologous envelopes to which individuals are exposed [56 ,79] , and the relationship between autologous and heterologous neutralization warrants further study. Second, identification of AnAb epitopes allows delineation of vulnerabilities on transmitted envelopes, which are exposed and immunogenic [74] , providing information that may contribute to vaccine design. The identification of common regions [12 ] (Moore et al., in preparation) involved in autologous neutralization may facilitate the development of multivalent vaccine candidates focused on limited regions of the envelope but better encompassing the diversity therein. 
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